Cart
sales@molnova.com
Stafib-2
CAS No. 2097938-74-2
Stafib-2( Stafib 2 )
Catalog No. M13314 CAS No. 2097938-74-2
Stafib-2 (Stafib 2) is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 736 | In Stock |
|
| 5MG | 519 | In Stock |
|
| 10MG | 739 | In Stock |
|
| 25MG | 1093 | In Stock |
|
| 50MG | 1442 | In Stock |
|
| 100MG | 1972 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameStafib-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionStafib-2 (Stafib 2) is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a.
-
DescriptionStafib-2 (Stafib 2) is a potent, selective small molecule inhibitor of transcription factor STAT5b with Ki of 9 nM, >20-fold selectivity over STAT5a.
-
In VitroStafib-2 has an extremely high affinity for STAT5b (Ki=8.8 nM).Stafib-2 (3-10 μM; 4-48 h) does not show significant activity in K562 and MDA-MB-231 cells.
-
In Vivo——
-
SynonymsStafib 2
-
PathwayJAK/STAT Signaling
-
TargetSTAT
-
RecptorSTAT
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2097938-74-2
-
Formula Weight644.466
-
Molecular FormulaC28H26N2O12P2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (77.58 mM)
-
SMILES——
-
Chemical Name4-((2-(4-((4-phenoxyphenyl)carbamoyl)phenoxy)acetamido)methyl)-1,2-phenylene bis(dihydrogen phosphate)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Elumalai N, et al. Sci Rep. 2017 Apr 11;7(1):819.
molnova catalog
related products
-
BTA-9881
BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.
-
NSC 370284
NSC 370284 is a small molecule that directly binds to and inhibits STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo.
-
Palivizumab
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
